{"id":"biogeneric-epoetin","safety":{"commonSideEffects":[{"rate":"20-30","effect":"Hypertension"},{"rate":"5-15","effect":"Thromboembolism"},{"rate":"10-20","effect":"Headache"},{"rate":"5-10","effect":"Injection site reactions"},{"rate":"5-10","effect":"Fever"}]},"_chembl":{"chemblId":"CHEMBL2109092","moleculeType":"Protein"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Epoetin is a recombinant human erythropoietin that mimics the natural hormone responsible for regulating red blood cell production. It binds to erythropoietin receptors on erythroid progenitor cells in the bone marrow, triggering proliferation and differentiation into mature red blood cells. This mechanism is used therapeutically to treat anemia by restoring hemoglobin levels in patients with insufficient endogenous erythropoietin production.","oneSentence":"Biogeneric epoetin stimulates erythropoiesis by binding to the erythropoietin receptor on bone marrow progenitor cells, increasing red blood cell production.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:43:14.984Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Anemia associated with chronic kidney disease"},{"name":"Anemia in patients with cancer receiving chemotherapy"},{"name":"Anemia in patients undergoing major surgery"}]},"trialDetails":[{"nctId":"NCT00238043","phase":"PHASE3","title":"Cohort Study to Determine the Long-Term Safety and Efficacy of Biogeneric Epoetin Treatment for Renal Anemia","status":"UNKNOWN","sponsor":"Ministry of Health, Malaysia","startDate":"2005-08","conditions":"Chronic Kidney Disease, End-Stage Renal Failure, Anaemia","enrollment":2000}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Biogeneric Epoetin","genericName":"Biogeneric Epoetin","companyName":"Ministry of Health, Malaysia","companyId":"ministry-of-health-malaysia","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Biogeneric epoetin stimulates erythropoiesis by binding to the erythropoietin receptor on bone marrow progenitor cells, increasing red blood cell production. Used for Anemia associated with chronic kidney disease, Anemia in patients with cancer receiving chemotherapy, Anemia in patients undergoing major surgery.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}